Keyphrases
Aerosolized Liposomal Amphotericin B
100%
Invasive Pulmonary mucormycosis
100%
Liposomal Amphotericin B
71%
Treatment Group
28%
No Significant Difference
14%
Survival Rate
14%
Female Mice
14%
Immunohistochemical Analysis
14%
Improved Survival
14%
Lung
14%
Life-threatening
14%
Immunohistochemical Study
14%
Histopathological Examination
14%
Pathological Findings
14%
Inhalation
14%
Immunocompromised Patients
14%
Infected Mice
14%
High Dose
14%
Lung Tissue
14%
Fungal Infection
14%
Cyclophosphamide
14%
Colony Forming Units
14%
Immunosuppressed
14%
Recommended Treatment
14%
Mucormycosis
14%
Inhalation Therapy
14%
Fungal Burden
14%
Group Finding
14%
R. Oryzae
14%
Cortisone Acetate
14%
Rhizopus Oryzae
14%
Conidia
14%
Immunology and Microbiology
Exhalation
100%
Survival Rate
50%
Immunocompromised Patient
50%
Oryza
50%
Drug Megadose
50%
Colony Forming Unit S
50%
Cyclophosphamide
50%
Rhizopus oryzae
50%
Immunology
50%
Conidium
50%
Medicine and Dentistry
Mucormycosis
100%
Amphotericin B
100%
Lung
16%
Survival Rate
8%
Histopathology
8%
Infection
8%
Drug Megadose
8%
Mycosis
8%
Cyclophosphamide
8%
Immunocompromised Patient
8%
Colony Forming Unit S
8%
Rhizopus arrhizus
8%
Inhalational Drug Administration
8%
Cortisone Acetate
8%
Exhalation
8%
Pharmacology, Toxicology and Pharmaceutical Science
Amphotericin B
100%
Mucormycosis
100%
Survival Rate
8%
Infection
8%
Immunocompromised Patient
8%
Mycosis
8%
Cyclophosphamide
8%
Oryza
8%
Cortisone Acetate
8%
Rhizopus arrhizus
8%
Conidium
8%